SPH4336 not checked
Shanghai Pharmaceuticals Holding Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SPH4336 Tablets :Orally, 400mg once a day; 28 days/cycle Letrozole tablets :Orally, 2.5mg once a day; 28 days/cycle”In the company’s words, NCT05744687 on ClinicalTrials.gov
- Tested for
- Locally Advanced or Metastatic Breast Cancer (2 trials), Breast Cancer Brain Metastases, Advanced Solid Tumors
- Main trialPhase 2/3
- “This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer”In the company’s words, NCT05744687 on ClinicalTrials.gov
Other drugs for Locally Advanced or Metastatic Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
Coming up3
- 1 DecPhase 2/3 trial completes · ClinicalTrials.gov
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
- 31 DecPhase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 31 May 2026 | Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer | |
| Phase 2/3Recruiting | 1 Dec 2026 | Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer | |
| Phase 2Recruiting | 31 Dec 2026 | Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. | |
| Phase 1/2Recruiting | 31 Dec 2026 | A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | |
| Phase 2Terminated | 4 Oct 2024 | Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas | |
| Phase 1/2Completed | 26 Oct 2023 | Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026